RAINFOREST Method for Predicting Treatment Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting treatment benefit in clinical trials face challenges due to the lack of available training labels and the high dimensionality of genome-wide germline variation datasets, leading to issues like overtraining and inefficiency in identifying subgroups of patients who benefit more from specific treatments.
Innovation Solution
The RAINFOREST method uses a random forest model with a novel splitting criterion based on survival difference (SurvDiff) to identify genetic markers and gene expression signatures that distinguish between treatment benefits, allowing for the prediction of better survival outcomes with one treatment compared to an alternative, without relying on predefined class labels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional random forest models or univariate analysis are used to identify treatment benefit predictors, then the method is simpler to implement, but the predictive performance is insufficient and overtraining occurs due to high dimensionality of genome-wide data
Solution Approach 1:
The patent segments the high-dimensional genome-wide data into manageable components by using survival difference calculations for individual genetic markers and genes, then integrates these segmented results through a random forest model to achieve both simplicity and predictive accuracy
Solution Approach 2:
The patent introduces survival difference (SurvDiff) as an intermediary metric that bridges the gap between raw high-dimensional genomic data and treatment benefit prediction, enabling the random forest model to effectively process genome-wide variation data without overtraining
2Reliability
If genome-wide germline variation datasets are analyzed to identify treatment predictors, then comprehensive coverage of genetic factors is achieved, but overtraining occurs due to high dimensionality
Solution Approach 1:
The patent extracts the essential signal from genome-wide data by calculating survival differences for individual genetic markers and genes, separating the relevant treatment benefit information from the high-dimensional noise to prevent overtraining while maintaining prediction reliability
Solution Approach 2:
The patent performs preliminary survival difference calculations for all genetic markers and genes before feeding them into the random forest model, preparing the data in advance to reduce computational burden during model training and prevent overtraining
3Productivity
If current methods are used to predict treatment benefit, then the analysis can be completed, but the ability to identify subgroups of patients who benefit more from specific treatments is insufficient
Solution Approach 1:
The patent uses survival difference as a feedback metric that quantifies the treatment benefit for each genetic marker and gene, allowing the random forest model to iteratively improve its ability to identify patient subgroups with differential treatment responses
Data Source
AI summary
The disclosure relates to methods of signatures which can be used in order to classify patients and predict responsiveness to therapy. In particular, the disclosure relates to RAINFOREST (tReAtment benefit prediction using raNdom FOREST), a new method to discover signatures capable of identifying a subgroup of patients more likely to benefit from a specific treatment as compared to another treatment.